Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Total Debt: 2017-2021

Historic Total Debt for Sunshine Biopharma (SBFM) over the last 3 years, with Dec 2021 value amounting to $1.9 million.

  • Sunshine Biopharma's Total Debt rose 100.21% to $1.9 million in Q4 2021 from the same period last year, while for Dec 2021 it was $7.2 million, marking a year-over-year increase of 663.49%. This contributed to the annual value of $1.9 million for FY2021, which is 100.21% up from last year.
  • Per Sunshine Biopharma's latest filing, its Total Debt stood at $1.9 million for Q4 2021, which was down 40.70% from $3.2 million recorded in Q3 2021.
  • In the past 5 years, Sunshine Biopharma's Total Debt ranged from a high of $3.2 million in Q3 2021 and a low of $27,541 during Q3 2019.
  • Its 3-year average for Total Debt is $1.2 million, with a median of $949,006 in 2020.
  • Its Total Debt has fluctuated over the past 5 years, first plummeted by 91.19% in 2019, then skyrocketed by 3,148.59% in 2021.
  • Quarterly analysis of 5 years shows Sunshine Biopharma's Total Debt stood at $79,710 in 2017, then spiked by 289.81% to $310,718 in 2018, then tumbled by 91.19% to $27,541 in 2019, then soared by 126.90% to $949,006 in 2020, then skyrocketed by 100.21% to $1.9 million in 2021.
  • Its Total Debt stands at $1.9 million for Q4 2021, versus $3.2 million for Q3 2021 and $2.1 million for Q2 2021.